ArticleACS omega2025
Formulation and Evaluation of a Silymarin Inclusion Complex-Based Gel for Skin Cancer.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Silymarin and Silybin: Rejuvenating Traditional Remedies with Modern Delivery Strategies.Pharmaceutics · 2025Review
- Cyclodextrin-Based Delivery Systems for Flavonoids: Mechanisms, Advances, Formulation, and Application Opportunities.Antioxidants (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Silymarin (SLM) is a bioactive, water-insoluble flavonoid reported against different types of cancer. In the present research, the SLM inclusion complex was prepared by the freeze-drying method using different cyclodextrins. The phase solubility study was performed to assess the stability constant and complexation efficiency. The prepared SLM inclusion complexes (F1, F2, and F3) were characterized for different physicochemical and in vitro parameters. Based on the results, the selected inclusion complex (F2) was converted to a topical gel. Finally, it was evaluated for antioxidant, protein denaturation, and cell viability assay (B16F10; skin cancer cell line). The in vitro results were further confirmed by performing a molecular docking study. The phase solubilization results showed the formation of a stable complex with a stability constant value of 548 mol L
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.